Christoph Bock is a Principal Investigator at the CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences and a Professor of [Bio]Medical Informatics at the Medical University of Vienna. His research combines experimental biology (high-throughput sequencing, epigenetics, CRISPR screening, synthetic biology) with computational methods (bioinformatics, machine learning, artificial intelligence) – for cancer, immunology, and precision medicine.

 

Before coming to Vienna, he was a postdoc at the Broad Institute of MIT and Harvard (2008-2011) and a PhD student at the Max Planck Institute for Informatics (2004-2008). Christoph Bock is also the scientific coordinator of the Biomedical Sequencing Facility of CeMM and MedUni Vienna, a member of the Human Cell Atlas Organizing Committee, a fellow of the European Lab for Learning and Intelligent Systems (ELLIS), and an elected board member of the Young Academy in the Austrian Academy of Sciences.

 

He has received important research awards, including ERC Starting Grant (2016-2021), ERC Consolidator Grant (2021-2026), Otto Hahn Medal of the Max Planck Society (2009), Overton Prize of the International Society for Computational Biology (2017), and Erwin Schrödinger Award of the Austrian Academy of Sciences (2022). He has been included in the global list of “Highly Cited Researchers” (Clarivate/ISI) each year since 2019. He co-founded Myllia Biotechnology, a Vienna-based biotech company that develops and applies single-cell methods for drug discovery.